Scholar Rock - Springer. Apitegromab. Muscle Revolution - $SRRK

Podcast: Empor.top - The Stories of Top Companies · Empor.top

Opublikowano: 2026-09-30

After solving a decades-old biological puzzle to selectively prevent muscle wasting, Cambridge-based Scholar Rock built a $5.7 billion market valuation on the back of pivotal Phase 3 success in spinal muscular atrophy. Yet as the pre-revenue enterprise approaches a critical September 2026 FDA action date for its lead drug, apitegromab, its near-term fate hinges less on clinical trial results than on resolving a third-party manufacturing compliance delay. Balancing an idle commercial infrastructure against a deliberate decision to step back from the lucrative GLP-1 obesity market, Scholar Rock embodies a high-stakes corporate drama: a company with validated science and massive market expectations that...